DEF: Fulgent Genetics Announces Details for 2025 Annual Stockholders Meeting

Fulgent Genetics sets date and agenda for its 2025 Annual Meeting of Stockholders, including director elections and executive compensation approval.

Summary

• Fulgent Genetics, Inc. will hold its 2025 Annual Meeting of Stockholders on May 15, 2025, at 9:00 a.m. Pacific Time, at the company's offices in El Monte, California.
• Stockholders will vote to elect four directors, ratify the appointment of Deloitte & Touche LLP as the independent accounting firm, and approve executive compensation.
• The board of directors recommends voting in favor of all three proposals.
• The company has elected to deliver proxy materials to most stockholders over the Internet to conserve resources and lower costs.
• The record date for determining stockholders eligible to vote is March 20, 2025.
• As of March 20, 2025, there were 30,865,730 shares of common stock outstanding and entitled to vote.
• The company's core revenue grew by 7% year-over-year in 2024, driven by precision diagnostics revenue.
• Fulgent Genetics completed the fiscal year 2024 with $828.6 million in cash, cash equivalents, restricted cash, and marketable securities.

Sentiment

Score: 6

Explanation: The document is neutral. While there's growth in core revenue and a strong cash position, the overall revenue decreased and EBITDA is negative. The document focuses on procedural matters related to the annual meeting.

Positives

• The company experienced significant annual core revenue growth, including growth of 7% year-over-year in 2024 and a compound annual core revenue growth of 24% from 2022 to 2024.
• The company maintains a strong balance sheet with $828.6 million in cash, cash equivalents, restricted cash, and marketable securities.
• The company's employee retention rate in 2024 was 79%.

Negatives

• Total revenue decreased by 2% year-over-year in 2024.
• Core EBITDA was negative in 2022, 2023 and 2024.

Risks

• The company's business results are subject to a variety of risks described in the Annual Report on Form 10-K for the year ended December 31, 2024.
• The company faces business, operational, strategic, research and development, cybersecurity, financial, and legal and regulatory risks.

Future Outlook

The company expects to begin enrollment of a Phase 1/1b clinical trial of FID-022 in mid-2025.

Management Comments

• Ming Hsieh, Chief Executive Officer, expressed gratitude for stockholders' continued support.

Industry Context

The company's growth in core revenue was driven mainly by the precision diagnostics revenue, which improved in both reproductive health services, as well as legacy diagnostic offerings.

Comparison to Industry Standards

• The peer group market for the Company includes 11 healthcare and diagnostics and research companies.
• The companies included in the peer group are identified by the compensation consultant and reviewed by the Compensation committee on an annual basis.
• Peer organizations are located within a multi-state geographic region and are of comparable market capitalization and revenue size to the Company.
• The companies that are included in the peer group have market capitalization or revenue that are 0.25x to 2.5x that of the Company.
• The peer group companies remain in the peer group each year to maintain a stable and consistent market pay measure, with additions and deletions occurring when required to assure comparability to the Company and to reflect mergers and acquisitions.
• The following list includes all peer group companies used for the current period: 23andMe Holding Co., Biodesix, Inc., CareDx, Inc., Castle Biosciences, Inc., GeneDx Holdings Corp., Guardant Health, Inc., Myriad Genetics, Inc., NeoGenomics, Inc., Opko Health, Inc., Pacific Biosciences of California, Inc., Veracyte, Inc.

Related Party Transactions

• The Company incurred $2.1 million in expenses in the year ended December 31, 2024, related to the licensing and development services and purchase of equipment from ANP Technologies, Inc., of which Mr. Hsieh is on the board of directors and an approximately 20% owner.
• On November 7, 2022, as consideration for the Merger, the Company paid an aggregate of approximately $100 million in exchange for all of the outstanding equity interests of Fulgent Pharma, comprised of approximately $43.4 million in cash and approximately $30.7 million in the Companys common stock, subject to customary adjustments for closing cash, closing indebtedness, transaction expenses and other transaction matters, for the acquisition of Fulgent Pharma which was 100% owned by Mr. Hsieh, the Chief Executive Officer and Chairperson of the Companys Board of Directors, and the Hsieh Family Dynasty Trust, dated January 27, 2010 (the Hsieh Trust), of which Mr. Hsieh is the grantor.

Stakeholder Impact

• Stockholders are invited to attend the Annual Meeting and vote on key proposals.
• Executive officers are incentivized through compensation plans tied to company performance.
• Employees are impacted by the company's sustainability efforts and corporate governance policies.

Next Steps

• Stockholders are encouraged to vote promptly by Internet, telephone, or mail.
• The company expects to begin enrollment of a Phase 1/1b clinical trial of FID-022 in mid-2025.

Key Dates

Keywords

Annual Meeting, Stockholders, Proxy Statement, Executive Compensation, Board of Directors, Fulgent Genetics, Election of Directors, Deloitte & Touche, Core Revenue, Core EBITDA